Fu Hong Han Lin (02696): HLX13 first-line application for phase 1 clinical trial of patients with unresectable hepatocellular carcinoma (HCC) was approved by the US FDA

Zhitongcaijing · 09/29/2025 09:17

Zhitong Finance App News, Fu Hong Han Lin (02696) announced that recently, the company's self-developed phase 1 clinical trial application (IND) for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) was approved by the US Food and Drug Administration (FDA). HLX13 The company plans to conduct this international multi-center clinical trial in the US when conditions are met.